SocialPicks.com: Recent activities for PBIO

Pressure BioSciences Inc. (PBIO, rated BUY)

Marian Filo — Thu, 03 Jul 2008 22:00:43 -0000

Pressure BioSciences, Inc., a life sciences company, engages in the research, development, and commercialization of pressure cycling technology (PCT) that uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. The company offers Barocycler instrumentation, which includes Barocycler NEP3229 that is capable of processing up to three samples simultaneously using its single-use PULSE Tubes; and Barocycler NEP2320, which processes one sample at a time and works on compressed air. It also provides consumable products comprising PULSE Tubes/FT500 that transmits the power of PCT from the Barocycler instrument to the sample; and ProteoSolve, a PCT-dependent method for the reproducible extraction of proteins from lipid-rich samples, including adipose and brain tissues, organelles, and membrane preparations. PCT has applications in a various life sciences areas, including sample preparation for genomic, proteomic, and small molecule studies; control of chemical (enzymatic) reactions; protein purification; pathogen inactivation; and immunodiagnostics. Its customers include researchers at academic laboratories, government agencies, and biotechnology, pharmaceutical, and other life sciences companies in the United States. The company was founded in 1978. It was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in 2004. Pressure BioSciences is based in South Easton, Massachusetts.

Pressure BioSciences Inc. (PBIO) Hires Matthew Potter to Join Management Team as the Vice President of Sales (PBIO, rated BUY)

quality stocks — Wed, 12 Mar 2008 01:49:29 -0000

Today Pressure BioSciences Incorporated announced that it has added a new member to its senior executive management team; Vice President of Sales. Matthew B. Potter will now oversee Pressure Biosciences’ seven US-based, regional sales directors and will be responsible for driving the Company’s commercialization of their novel and patented pressure cycling technology (PCT) product line. Matthew Potter brings just short of twenty years of sales and management experience in both the pharmaceutical and biotechnology fields.

Potter has been a Sales Manager at Pharmacia Biotech; National Sales Director at Visible Genetics; Director, Sales and Marketing at MicroCal, LLC; National Sales Manager, Key Accounts — Pharma at Qiagen, Inc; and Vice President of Sales and Marketing at Abcam, Inc. Before his transition into sales, Mr. Potter was a researcher at the Worcester Foundation for Experimental Biology. Mr. Potter holds a BA in Biology from Clark University and an MBA from Assumption College, both located in Worcester, MA.

Potter said, “In over 19 years of selling products into the research marketplace for the analysis of nucleic acids, proteins, and small molecules, one issue — how to achieve high quality extraction of bio- molecules prior to analysis — nearly always rose to the top. This was always a key issue, and to that end, I believe strongly that the PCT Sample Preparation System answers many of the sample preparation problems that researchers encounter, and offers unique advantages to customers looking to extract DNA, RNA, proteins, and small molecules from a wide variety of biological samples. PBI has a dedicated and talented group of people throughout the organization, and I look forward to working with them — and in particular our newly hired field sales organization — to drive this technology into the marketplace.”

The addition of Potter was meant to give Dr. Nathan Lawrence, who previously led sales and marketing, an opportunity to focus solely on marketing both domestically and abroad. PBI’s Founder, President, and CEO, Richard T. Schumacher, said, “This new focus for Dr. Lawrence will allow us to align our sales and marketing efforts in a manner that supports our Company’s transition to a fully commercial operation in 2008.”

Please see disclaimer on QualityStocks.net website

Pressure Biosciences, Inc. (PBIO) - Equipped with Product Line to Fight Disease (PBIO, rated BUY)

quality stocks — Thu, 06 Mar 2008 19:46:50 -0000

Founded in 1978, Pressure Biosciences (NASDAQ: PBIO) began significant operations in 1986 and went public 10 years later in 1996, under its former name, Boston Biomedica, Inc. Today the company holds 13 U.S. patents and four foreign patents for applications of its Pressure Cycling Technology (PCT), used in the healthcare field for genomics, proteomics and nucleic acid testing with the ability to rupture cells to release significantly more proteins in fatty tissue.

The company’s PCT Sample Preparation System (PCT SPS) allows for the safe, rapid and reproducible extraction of DNA, RNA, small molecules and proteins. PCT SPS combines the company’s Barocycler NEP3229 with its PULSE Tubes to process and extract up to three samples of animal, plant or microbial samples which can be processed and extracted within minutes. The system’s computer-controlled protocols ensure consistent sample extraction.

Pressure Bioscience’s technology is applicable to various life sciences areas, drawing customers from academic laboratories, government agencies and biotechnology sectors.

The products are used to further the study of various diseases such as heart disease, strokes, cancer and diabetes. The company’s product line includes its latest product, the ProteoSolve Kit, assisting in the research of obesity; the Barocycler NEP2320, Barocycler NEP3229; and its aforementioned PULSE Tubes.

Please see disclaimer on QualityStocks.net website

Expanded Sales Force Earns Pressure BioSciences, Inc. (PBIO) a “Speculative Strong Buy” Rating and Increased Sales (PBIO, rated BUY)

quality stocks — Wed, 27 Feb 2008 23:54:36 -0000

Dutton Associates recently rated Pressure BioSciences, Inc. (NASDAQ: PBIO) as a “Speculative Strong Buy,” pricing the 12-month target at $10 per share. The research report commends the company on its “unique and superior technology” applicable to a variety of areas in the life-sciences field.

As Pressure BioSciences utilizes its expanded sales force, Dutton said it expects sales to increase in the upcoming quarters of 2008. The company’s Commercialization Plan called for the addition of seven full-time sales directors to help the company spread its regional coverage.

The sales force is responsible for the marketing of the Barocylcer NEP3229, the Barocycler NEP2320, PULSE Tubes (used in conjunction with the Barocyclers), and the company’s most recent product, ProteoSolve.

The company’s base technology is Pressure Cycling Technology (PCT), a sample preparation system that uses rapid, repeated, alternating cycles of hydrostatic pressure for cell component extraction. The company’s technology and instruments are used to further studies against obesity and related diseases through the research and development of sample preparation for genomic, proteomic and small molecule studies.

In November 2007, Pressure BioSciences announced an increase in its sales of the Barocycler NEP 3229 and an order from its manufacturer for 20 additional units. It also announced the installation of four Barocycler NEP2320 instruments, and an order for 40 more units from the company’s manufacturer.

Please see disclaimer on QualityStocks.net website

Pressure Biosciences, Inc. (PBIO) Rolls Out New ProteoSolveLRS Kit to Battle Obesity (PBIO, rated BUY)

quality stocks — Fri, 15 Feb 2008 23:04:39 -0000

According to the most recent National Health and Nutrition Examination survey, roughly two-thirds of the adults in the United States are overweight, slowly closing the gap between themselves and the one-third of Americans considered obese. Analyzing the protein from lipid-rich tissues helps researchers understand the disease that kills about 300,000 people each year in the U.S. Additionally, obesity is linked to heart disease, stroke, cancer and diabetes.

PressureBiosciences, Inc. (NASDAQ: PBIO) developed Pressure Cycling Technology (PCT) which uses cycles of hydrostatic pressure, as well as other patented technology applicable in the life sciences field for genomic and proteomic sample preparation, pathogen inactivation, control of enzymes, immunodiagnostics and protein purification.

The company recently rolled out the new detergent-free ProteoSolveLRS Kit, to be used in collaboration with PCT to extract proteins from lipid-rich samples. The ProteoSolveLRS lack of detergents gives it an upper hand over traditional methods that can produce disappointing results, thereby interfering with analytical methods.

According to Pressure Biosciences, when ProteoSolveLRS is used with PCT, it is possible to divide the lipid and protein components within a sample, allowing for higher protein recovery and reproducibility compared to traditional detergent-based methods. It also allows researchers to identify novel proteins, analyze lipid composition and discover biomarkers, all important to the fight against obesity.

Please see disclaimer on QualityStocks.net website

Pressure BioSciences Inc. (PBIO) is a BUY

quality stocks — Fri, 25 Jan 2008 02:47:07 -0000

BUY rating on Pressure BioSciences Inc. (PBIO)

Start Price: $4.9
Start Date: 01/25/2008

Pressure BioSciences Inc. (PBIO) is a SELL

jpcoombs — Tue, 27 Mar 2007 18:18:16 -0000

SELL rating on Pressure BioSciences Inc. (PBIO)

Start Price: $4.05
Start Date: 03/27/2007

Pressure BioSciences Inc. (PBIO) is a BUY

jpcoombs — Fri, 23 Mar 2007 03:26:51 -0000

BUY rating on Pressure BioSciences Inc. (PBIO)

Start Price: $4.31
Start Date: 03/23/2007

Pressure BioSciences Inc. (PBIO) is a HOLD

jpcoombs — Mon, 12 Mar 2007 21:58:28 -0000

HOLD rating on Pressure BioSciences Inc. (PBIO)

Start Price: $4.22
Start Date: 03/12/2007

Pressure BioSciences Inc. (PBIO) is a BUY

Johns Wu — Thu, 05 Oct 2006 01:49:15 -0000

BUY rating on Pressure BioSciences Inc. (PBIO)

Start Price: $3.75
Start Date: 10/05/2006